The nation’s drug problem is commercial recreational pharmacology

The nation’s drug problem is commercial recreational pharmacology
Drs. Robert L. DuPont and Sharon Levy have written a brilliant paper that calls on us to view the drug problem as commercial recreational pharmacology, which they define as “the personally controlled use of psychoactive drugs that super-stimulate brain reward for pleasure.” Greater acceptance of drug use and its commercialization is exacting a toll on the nation’s public health. One example is a decline in US life expectancy, which fell three years in a row from 2016 and was driven by overdose deaths.

The researchers explain that until the 1960s, most drug use was confined to just a few drugs. But as the baby boom generation became adolescents, drug use began to be more tolerated, and an array of drugs gradually became available. This shift led to today’s opioid epidemic, marijuana legalization, and the youth vaping epidemic.

New drugs and new ways to consume them add up to huge profits for their makers. Americans spend $254 billion on alcohol, $125 billion on tobacco, and $150 billion on illicit drugs.  And thus, the acceptance of recreational pharmacology in the 60s has morphed into commercialized recreational pharmacology today.

The researchers advise “a seismic shift in our shared cultural understanding of recreational drug use from one promoted by both legal and illegal commercial interests to one based on public health science that recognizes recreational drug use as a major health risk behavior.”

We highly recommend this paper to our readers for the authors’ insights into the overall drug problem and their intelligent advice on how we can resolve it. Only the abstract is available for free, but you can “rent” the article for 48-hour online access for $7. It’s well worth the money.

Read Alcoholism and Drug Abuse Weekly abstract here.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Related Posts

IASIC Speaker Series Presents: Impacts of Maternal Cannabis Use on Long-Term Psychiatric Risk

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Libby Stuyt Interview on Randy Tobler show

Exciting News! Libby Stuyt’s Interview on Randy Tobler Show! Hey everyone, we wanted to share some thrilling news! The brilliant Dr. Libby Stuyt recently had an enlightening interview on Randy Tobler Show. Dr. Stuyt is known for her groundbreaking work in the field of addiction medicine and mental health. Her insights are nothing short of

Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

Introduction Cannabis contains over 100 cannabinoids, of which Δ9-tetrahydrocannabinol and cannabidiol are the most clinically relevant. Tetrahydrocannabinol is a partial agonist at CB1 and binds CB2 receptors. CB1 is widely expressed by central and peripheral neurones but also by immune cells and other type of cells in the brain and in the periphery, and when

Medical marijuana access and prolonged opioid use among adolescents and young adults

Abstract Background and Objectives Laws liberalizing access to medical marijuana are associated with reduced opioid analgesic use among adults, but little is known about the impact of such policies on adolescents and young adults. Methods This retrospective cohort study used 2005 to 2014 claims from MarketScan® Commercial database, which covers all 50 states and Washington

Scroll to Top